Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

Genes Chromosomes and Cancer

Volumn 45, Issue 11, 2006, Pages 1033-1040

  Bergamaschi, Anna ^a,b   Kim, Young H ^b   Wang, Pei ^c,f   Sørlie, Therese ^a   Hernandez Boussard, Tina ^c   Lonning, Per E ^d   Tibshirani, Robert ^c   Børresen Dale, Anne Lise ^a,e   Pollack, Jonathan R ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN RECEPTOR; PROTEIN P53;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GRADING; CHROMOSOME ABERRATION; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA CONTENT; DNA COPY NUMBER; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE LOSS; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; SURVIVAL RATE;

EID: 33748939380     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20366     Document Type: Article

References (38)

1. Adhikary S, Eilers M. 2005. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6:635-645.
2. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. 2005. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1):S135-S144.
3. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G. 2004. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534-8540.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717.
5. Eden P, Ritz C, Rose C, Ferno M, Peterson C. 2004. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837-1841.
6. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485.
7. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE. 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9:5582-5588.
8. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL. 2001. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505-2512.
9. Gollub J, Ball CA, Binkley G, Demeter J, Finkelstein DB, Hebert JM, Hernandez-Boussard T, Jin H, Kaloper M, Macese JC, Schroeder M, Brown PO, Botstein D, Sherlock G. 2003. The Stanford Microarray Database: Data access and quality assessment tools. Nucleic Acids Res 31:94-96.
10. Gradishar WJ. 2005. The future of breast cancer: The role of prognostic factors. Breast Cancer Res Treat 89 (Suppl 1):S17-S26.
11. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM. 1995. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 147:905-911.
12. Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Lonning PE, Kaaresen R, Gray JW. 2001. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci USA 98:7952-7957.
13. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J. 2000. Amplification and deletion of: topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847.
14. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, Olsson H. 1997. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362-371.
15. Knuutila S, Autio K, Aalto Y. 2000. Online access to CGH data of DNA sequence copy number changes. Am J Pathol 157:689.
16. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-649.
17. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, Delrow JJ, Trask BJ, Hsu L, Porter PL. 2004. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64:8541-8549.
18. McGuire WL. 1978. Steroid receptors in human breast cancer. Cancer Res 38:4289-4291.
19. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. 1994. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266.
20. Nathanson KL, Shugart YY, Omaruddin R, Szabo C, Goldgar D, Rebbeck TR, Weber BL. 2002. CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Hum Mol Genet 11:1327-1332.
21. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826.
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Bocstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
23. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO. 1999. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41-46.
24. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99:12963-12968.
25. Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. 2005. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol 12:271-273.
26. Richard F, Pacyna-Gengelbach M, Schluns K, Fleige B, Winzer KJ, Szymas J, Dietel M, Petersen I, Schwendel A. 2000. Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89:305-310.
27. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. 2006. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121-132.
28. Ross JS, Fletcher JA. 1998. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413-428.
29. Schuler GD. 1997. Pieces of the puzzle: Expressed sequence tags and the catalog of human genes. J Mol Med 75:694-698.
30. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
31. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423.
32. Subramaniam DS, Isaacs C. 2005. Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol 6:147-159.
33. Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray JW, Kallioniemi OP, Isola J. 1995. Amplification of chromosomal region 20q13 in invasive breast cancer: Prognostic implications. Clin Cancer Res 1:1455-1461.
34. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP. 1997. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222-1227.
35. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121.
36. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
37. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. 2004. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64:64-71.
38. Yeon CH, Pegram MD. 2005. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 23:391-409.